Hepatitis C in patients with chronic kidney disease: the opportunity to eradicate it has come. Review of management in this population with the advent of new direct-acting antivirals
Abstract
With the advent of new direct-acting antivirals (DAA) for the treatment of Hepatitis C and their possible use in patients with endstage renal disease and kidney transplantation, the possibility of eradicating this infection in this population opens up. If achieved, it would have an enormous clinical effect given the higher rate of morbidity and mortality that this infection causes in such population, either due to its hepatic or extrahepatic complications, where glomerulopathies play a preponderant role. In this article we have focused on reviewing the pu-blished advances regarding the possible pathogenic role of C virus in the endothelial injury of renal patients, its incidence and clinical effect. We have also reviewed the recent KDIGO Clinical Practice Guideline regarding the treatment criteria and the type of regimen recommended in each scenario.References
World Health Organization. Global hepatitis report, 2017 [Intenet]. Geneva: WHO; 2017. 68 p. Disponible en: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1 (Consulta: 28/12/2017).
Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335-42.
Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90(11):1165-71.
Viganò M, Colombo M. Extrahepatic manifestations of Hepatitis C virus. Gastroenterol Clin North Am. 2015;44(4):775-91.
Ferri C, Giuggioli D, Colaci M. Renal manifestations of Hepatitis C virus. Clin Liver Dis. 2017;21(3):487-97.
Fabrizi F, Messa P, Martin P. The unravelled link between chronic kidney disease and Hepatitis C infection. New J Sci. 2014;2014:180203.
Lai TS, Lee MH, Yang HI, You SL, Lu SN, Wang LY, et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology. 2017;66(3):784-93.
Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61(5):1495-502.
Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: 10) Fabrizi F, Martin P, Dixit V, Messa P. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7(4):549-57.
Younossi ZM. Hepatitis C infection: a systemic disease. Clin Liver Dis. 2017;21(3):449-53.
Viganò M, Colombo M. Extrahepatic Manifestations of Hepatitis C Virus. Gastroenterol Clin North Am. 2015;44(4):775-91.
Lin YJ, Shaw TG, Yang HI, Lu SN, Jen CL, Wang LY, et al. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. Liver Int. 2017;37(2):179-86.
Ruhl CE, Menke A, Cowie CC, Everhart JE. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology. 2014;60(4):1139-49.
White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831-44.
Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56(5):1681-7.
Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59(4):1293-302.
Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, et al. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care. 2017;40(9):1173-80.
Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 2018;90(2):320-7.
Petta S, Macaluso FS, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more? Gut. 2014;63(3):369-75.
Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology. 2016;150(1):145-155.e4; quiz e15-6.
Tran TT, Metha D, Mensa FJ, Park C, Sanchez Y. Pan-genotypic hepatitis C treatment with glecaprevir + pibrentasvir resulted in improvement in cardiovascular and metabolic extrahepatic manifestations and stable renal function: Results from phase 3 clinical trials [abstract]. Hepatology. 2017;61(Suppl 1):633A.
Ferri C, Giuggioli D, Colaci M. Renal manifestations of hepatitis C virus. Clin Liver Dis. 2017;21(3):487-97.
Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167(12):1271-6.
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153-94.
KDIGO 2017 Clinical Practice Guideline on the Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in CKD (Public Review Draft) [Internet]. Providence; 2017, xix, 108 p. Disponible en: http://kdigo.org/clinical_practice_guidelines/Hep%20C/KDIGO%202017%20Hep%20C%20GL%20Public%20Review%20Draft%20FINAL.pdf (Consulta: 28/12/2017).
Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537-45.
Reddy KR, Roth D, Bruchfeld A, Hwang P, Haber B, Robertson MN, et al. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatol Res. 2017;47(12):1340-5.
Gane E, Sola R, Cohen E, Roberts SK, George J, Skoien R, et al. RUBY-II: Efficacy and Safety of a Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir Regimen in Patients With Severe Renal Impairment or End-Stage Renal Disease and HCV Genotype 1a or 4 Infection. Hepatology. 2016;64 (Suppl 1):470A.
Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65(1):40-7.
Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, et al. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017;377(15):1448-55.
Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, et al. Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents. Am J Transplant. 2016;16(5):1588-95.
Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, et al. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. Am J Transplant. 2016;16(5):1474-9.
Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, et al. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. Ann Intern Med. 2017;166(2):109-17.
Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408-17.
Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473-82.
Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835-42.
